Here are the 424B prospectus supplements from INNOVATE Corp. (VATE) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow VATE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VATE filings page.
INNOVATE Corp. is establishing an at-the-market equity program to sell up to $31 million of common stock through Jefferies LLC under an open market sales agreement. Jefferies will act as sales agent on a commercially reasonable efforts basis and receive a 3.0% commission on gross proceeds, with sales executed primarily on the New York Stock Exchange under the symbol VATE.
The company intends to use any net proceeds for general corporate purposes, including working capital, paying interest and potentially repaying, refinancing, redeeming or reducing outstanding indebtedness. As of June 30, 2026, INNOVATE had $732.2 million of consolidated debt and historical net tangible book value of $(37.32) per share, leading to modeled immediate dilution of $41.73 per share at an assumed price of $12.11.
INNOVATE is pursuing major asset sales, including the DBMG Sale and the Spectrum Merger, which, if completed, would eliminate substantially all consolidated operating revenue and leave the company dependent on transaction proceeds, minority investments and its Life Sciences and Other segments. The company discloses substantial doubt about its ability to continue as a going concern and warns that stockholders should not expect to receive proceeds from the DBMG Sale, which are expected to be applied to debt obligations.